Clinical Trials > Targeted Therapy

Learn more about Targeted Therapies.

It is not the intention of the Cholangiocarcinoma Foundation to provide specific medical advice.  We provide website users with information to help them better understand their health conditions and the current approaches related to prevention, diagnosis, treatment and supportive care. You are urged to always seek the advice of your physician or other qualified healthcare provider.

Now Enrolling

A Study to Evaluate KIN-3248 (study drug) in Patients with Advanced Tumors Who Have FGFR2 and//or FGFR3 Gene Alterations

This is an open label study in adults with advanced tumors who have FGFR2 and/or FGFR3 mutations. Participants receive daily medicine by mouth of KIN-3248 (study drug) with periodic study visits (ranging from weekly at the beginning of the trial to monthly) to have laboratory testing, imaging assessments and safety exams such as ECG, physical exam

Read More

A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

The study drug, ENV-101, acts on a protein in the body that is thought to be involved with the
growth of these abnormal cells caused by a mutation of a gene, PTCH1. By blocking this
process, ENV-101 may slow the progress of the disease or you may have a partial or complete
response.

Read More

First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

This clinical trial is studying the safety and effectiveness of an investigational drug for patients with Cholangiocarcinoma and other solid tumors that meet eligibility requirements. This investigational drug is a highly selective Fibroblast Growth Factor Receptor 2 (FGFR2) inhibitor. Please refer to Clinicaltrials.gov for more information.

Read More

ZW25-201: A Phase 2 Study of Zanidatamab (ZW25; bispecific antibody) Plus First-line Chemotherapy in HER2-Expressing Cancers, Including Cholangiocarcinoma (Bile Duct Cancer), Gallbladder Cancer, and Colorectal Cancer

To investigate the efficacy and safety of zanidatamab in combination with standard first line chemotherapy regimens in gastrointestinal cancers, including biliary tract cancer (BTC) such as intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer.

Read More

Safety and Tolerability of TNG908 in Patients with MTAP-deleted Solid Tumors

Study Name Safety and Tolerability of TNG908 in Patients with MTAP-deleted Solid Tumors ClinicalTrials.gov Identifier (if applicable) NCT05275478 Clinical Trial Category (check all that apply) Beyond First Line Therapy Targeted Therapy Study Center Institution Name NEXT Oncology Institution Address 2829 Babcock Road City San Antonio State Texas Zip Code 78229 Country United States List additional…

Read More

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

This EAP is to provide expanded access of adagrasib (MRTX849) to patients with previously treated advanced solid tumors harboring a KRAS G12C mutation.

Read More

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual. The solid tumors studied in this trial have either spread to other parts of the body or cannot be removed completely with surgery.
The trial will also look at what side effects happen

Read More

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

Read More

A Global Phase 2 Study to Evaluate the Efficacy and Safety of ARX788 for Selected HER2-mutated or HER2-amplified/over-expressed Solid Tumors

The study will enroll subjects with HER2-mutated or HER2-amplified/over-expressed locally advanced or metastatic solid tumor cancers whose prior standard of care therapies have failed. This trial will evaluate efficacy and safety of ARX788, an anti-HER2 drug conjugate across multiple cancer populations, as defined by HER2 genetic biomarkers.

Read More

HCRN GI19-414

This research study is aimed to find out if cholangiocarcinoma patients who have a certain type of cancer mutation and responded to platinum-based chemotherapy will benefit from the combination of niraparib (targeted therapy) and dostarlimab (immune therapy).

Read More